Stock Report

Download full stock data and analysis for free Last Updated: 09-Sep-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Altamira Therapeutics (CYTO) Key Ratios

Stock Card factsheet share-fund-plan-icon

$0.13

up-down-arrow $0.01 (10.18%)

As on 17-Jan-2025 09:30EDT

Market cap

info icon

$1 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

0.2

P/B Ratio

info icon

0.1

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 0.00 -- -342.93 -262.71 -201.87
EBIT 0.00 27.70 -18.82 6.45 8.98
Net Profit 0.00 -- 72.60 3.65 6.46
EPS -- -- -- -- --
Book Value -- -- -- -- --
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsDec-23Dec-22Dec-21
EBIT-Margin info -8,220.97-1,626.80---5,809.65-10,632.28
Net Margin info ----------
Return on equity info -181.10-150.43783.37-1,208.66-118.00
Return on Capital info -300.42-218.16-317.83-469.67-113.76
Return on Assets info -134.22-105.34-103.88-211.03-87.74
Debt to Equity (x) info ----0.02-0.760.05

Profitability

View Detailed Peer Comparison

ROCE

-317.83

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
Dec-23
Dec-22
Dec-21
Dec-20
Dec-19
Altamira Therapeutics (CYTO)
-317.83
-469.67
-113.76
-70.30
-119.27
Peer Median
--
--
--
--
--
ROE

783.37

--

Profit after tax / Average Net worth * 100

Company Name
Dec-23
Dec-22
Dec-21
Dec-20
Dec-19
Altamira Therapeutics (CYTO)
783.37
-1,208.66
-118.00
-71.91
-136.94
Peer Median
--
--
--
--
--
ROA

-103.88

--

Profit after tax / Average Total assets * 100

Company Name
Dec-23
Dec-22
Dec-21
Dec-20
Dec-19
Altamira Therapeutics (CYTO)
-103.88
-211.03
-87.74
-54.62
-69.43
Peer Median
--
--
--
--
--
EBIT Margin

--

--

Operating profit (EBIT) / Net Sales * 100

Company Name
Dec-23
Dec-22
Dec-21
Dec-20
Dec-19
Altamira Therapeutics (CYTO)
--
-5,809.65
-10,632.28
-3,028.04
12,962.76
Peer Median
--
--
--
--
--
Net Margin

--

--

Net profit / Total Income (Net sales plus other income) * 100

Company Name
Dec-23
Dec-22
Dec-21
Dec-20
Dec-19
Altamira Therapeutics (CYTO)
--
-8,680.31
-27,222.33
-4,699.91
11,842.68
Peer Median
--
--
--
--
--

Growth

View Detailed Peer Comparison

Revenue Growth

-1.00

--

Year on year growth in net sales

Company Name
Dec-23
Dec-22
Dec-21
Dec-20
Dec-19
Altamira Therapeutics (CYTO)
-1.00
3.78
-0.63
4.12
-1.04
Peer Median
--
--
--
--
--
EBIT Growth

59.05

--

Year on year growth in operating profit (EBIT)

Company Name
Dec-23
Dec-22
Dec-21
Dec-20
Dec-19
Altamira Therapeutics (CYTO)
59.05
-161.41
-28.56
27.22
33.73
Peer Median
--
--
--
--
--
Net Profit Growth

72.60

--

Year on year growth in profit after tax

Company Name
Dec-23
Dec-22
Dec-21
Dec-20
Dec-19
Altamira Therapeutics (CYTO)
72.60
-52.55
-112.07
-23.65
42.31
Peer Median
--
--
--
--
--

Solvency

View Detailed Peer Comparison

Debt to Equity

0.02

--

Total debt / Net worth

Company Name
Dec-23
Dec-22
Dec-21
Dec-20
Dec-19
Altamira Therapeutics (CYTO)
0.02
-0.76
0.05
0.03
--
Peer Median
--
--
--
--
--
Short term debt to equity ratio

0.02

--

(Short term borrowings / Net worth)

Company Name
Dec-23
Dec-22
Dec-21
Dec-20
Dec-19
Altamira Therapeutics (CYTO)
0.02
-0.72
0.01
0.03
--
Peer Median
--
--
--
--
--
Current Ratio

1.38

--

Current Assets / Current Liabilities and Provisions

Company Name
Dec-23
Dec-22
Dec-21
Dec-20
Dec-19
Altamira Therapeutics (CYTO)
1.38
0.14
0.77
3.83
1.04
Peer Median
--
--
--
--
--
Quick Ratio

1.46

--

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
Dec-23
Dec-22
Dec-21
Dec-20
Dec-19
Altamira Therapeutics (CYTO)
1.46
0.14
0.60
122.05
434.96
Peer Median
--
--
--
--
--
Interest Coverage

-7.04

--

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
Dec-23
Dec-22
Dec-21
Dec-20
Dec-19
Altamira Therapeutics (CYTO)
-7.04
-19.47
-35.81
-39.09
-253.57
Peer Median
--
--
--
--
--

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

--

--

Debtors outstanding / Net Sales * 100

Company Name
Dec-23
Dec-22
Dec-21
Dec-20
Dec-19
Altamira Therapeutics (CYTO)
--
2.14
34.04
46.35
-598.75
Peer Median
--
--
--
--
--
Asset Turnover

--

--

Sales / Average Total Assets

Company Name
Dec-23
Dec-22
Dec-21
Dec-20
Dec-19
Altamira Therapeutics (CYTO)
--
0.02
0.00
0.01
-0.01
Peer Median
--
--
--
--
--
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
Dec-23
Dec-22
Dec-21
Dec-20
Dec-19
Altamira Therapeutics (CYTO)
--
16.89
293.33
435.60
-2,138.26
Peer Median
--
--
--
--
--
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
Dec-23
Dec-22
Dec-21
Dec-20
Dec-19
Altamira Therapeutics (CYTO)
--
107.62
-29,125.82
--
--
Peer Median
--
--
--
--
--
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
Dec-23
Dec-22
Dec-21
Dec-20
Dec-19
Altamira Therapeutics (CYTO)
--
1,051.38
347.77
--
--
Peer Median
--
--
--
--
--
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
Dec-23
Dec-22
Dec-21
Dec-20
Dec-19
Altamira Therapeutics (CYTO)
--
-926.86
-29,180.26
--
--
Peer Median
--
--
--
--
--
loading...
loading...